SG11201805184TA - Combination therapy - Google Patents
Combination therapyInfo
- Publication number
- SG11201805184TA SG11201805184TA SG11201805184TA SG11201805184TA SG11201805184TA SG 11201805184T A SG11201805184T A SG 11201805184TA SG 11201805184T A SG11201805184T A SG 11201805184TA SG 11201805184T A SG11201805184T A SG 11201805184TA SG 11201805184T A SG11201805184T A SG 11201805184TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- lochside
- alaninyl
- benzoxy
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000003445 biliary tract Anatomy 0.000 abstract 1
- 201000009036 biliary tract cancer Diseases 0.000 abstract 1
- 208000020790 biliary tract neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 abstract 1
- 229950005566 picoplatin Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/054158 WO2017109444A1 (en) | 2015-12-23 | 2015-12-23 | Combination therapy |
| GBGB1609770.1A GB201609770D0 (en) | 2016-06-03 | 2016-06-03 | Combination therapy |
| PCT/GB2016/054018 WO2017109486A1 (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805184TA true SG11201805184TA (en) | 2018-07-30 |
Family
ID=57681677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805184TA SG11201805184TA (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20190022117A1 (enExample) |
| EP (2) | EP3738595A1 (enExample) |
| JP (1) | JP6898329B2 (enExample) |
| KR (1) | KR20180096698A (enExample) |
| CN (1) | CN108697725A (enExample) |
| AU (1) | AU2016375861B2 (enExample) |
| CA (1) | CA3008749C (enExample) |
| CY (1) | CY1122835T1 (enExample) |
| DK (1) | DK3393478T3 (enExample) |
| EA (1) | EA037459B1 (enExample) |
| ES (1) | ES2778933T3 (enExample) |
| HR (1) | HRP20200423T1 (enExample) |
| HU (1) | HUE050290T2 (enExample) |
| IL (1) | IL260076A (enExample) |
| LT (1) | LT3393478T (enExample) |
| MA (1) | MA51576A (enExample) |
| MD (1) | MD3393478T2 (enExample) |
| ME (1) | ME03677B (enExample) |
| MX (1) | MX383988B (enExample) |
| MY (1) | MY194629A (enExample) |
| PH (1) | PH12018501339A1 (enExample) |
| PL (1) | PL3393478T3 (enExample) |
| PT (1) | PT3393478T (enExample) |
| RS (1) | RS60211B1 (enExample) |
| SG (1) | SG11201805184TA (enExample) |
| SI (1) | SI3393478T1 (enExample) |
| SM (1) | SMT202000154T1 (enExample) |
| WO (1) | WO2017109486A1 (enExample) |
| ZA (1) | ZA201804155B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013346515B2 (en) | 2012-11-16 | 2017-05-25 | NuCana plc | Process for preparing nucleoside prodrugs |
| EA033046B1 (ru) | 2014-06-25 | 2019-08-30 | НУКАНА ПиЭлСи | Состав, содержащий пролекарство гемцитабина |
| RS60968B1 (sr) | 2014-06-25 | 2020-11-30 | NuCana plc | Prolekovi gemcitabina |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| PH12018500691B1 (en) | 2015-10-05 | 2022-08-10 | NuCana plc | Combination therapy |
| CA3007347C (en) | 2015-12-11 | 2020-08-04 | NuCana plc | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| EA201491629A1 (ru) * | 2012-08-13 | 2015-08-31 | Регулон, Инк. | Способы лечения рака с использованием липоплатина |
| JP6420247B2 (ja) * | 2012-11-13 | 2018-11-07 | ボーイエン セラピューティクス，インコーポレイティド | ゲムシタビンプロドラッグ及びその使用 |
| CN107835687A (zh) * | 2015-05-14 | 2018-03-23 | 努卡那有限公司 | 癌症治疗 |
| PH12018500691B1 (en) * | 2015-10-05 | 2022-08-10 | NuCana plc | Combination therapy |
-
2016
- 2016-12-21 SI SI201630680T patent/SI3393478T1/sl unknown
- 2016-12-21 CN CN201680082464.9A patent/CN108697725A/zh active Pending
- 2016-12-21 EA EA201891473A patent/EA037459B1/ru unknown
- 2016-12-21 CA CA3008749A patent/CA3008749C/en active Active
- 2016-12-21 PT PT168200053T patent/PT3393478T/pt unknown
- 2016-12-21 HU HUE16820005A patent/HUE050290T2/hu unknown
- 2016-12-21 EP EP20160070.7A patent/EP3738595A1/en not_active Withdrawn
- 2016-12-21 MD MDE20181039T patent/MD3393478T2/ro not_active IP Right Cessation
- 2016-12-21 US US16/065,498 patent/US20190022117A1/en not_active Abandoned
- 2016-12-21 WO PCT/GB2016/054018 patent/WO2017109486A1/en not_active Ceased
- 2016-12-21 KR KR1020187020533A patent/KR20180096698A/ko not_active Ceased
- 2016-12-21 MY MYPI2018001015A patent/MY194629A/en unknown
- 2016-12-21 DK DK16820005.3T patent/DK3393478T3/da active
- 2016-12-21 ES ES16820005T patent/ES2778933T3/es active Active
- 2016-12-21 ME MEP-2020-56A patent/ME03677B/me unknown
- 2016-12-21 SM SM20200154T patent/SMT202000154T1/it unknown
- 2016-12-21 MX MX2018007772A patent/MX383988B/es unknown
- 2016-12-21 HR HRP20200423TT patent/HRP20200423T1/hr unknown
- 2016-12-21 RS RS20200297A patent/RS60211B1/sr unknown
- 2016-12-21 AU AU2016375861A patent/AU2016375861B2/en not_active Ceased
- 2016-12-21 SG SG11201805184TA patent/SG11201805184TA/en unknown
- 2016-12-21 PL PL16820005T patent/PL3393478T3/pl unknown
- 2016-12-21 JP JP2018532746A patent/JP6898329B2/ja not_active Expired - Fee Related
- 2016-12-21 MA MA051576A patent/MA51576A/fr unknown
- 2016-12-21 EP EP16820005.3A patent/EP3393478B1/en active Active
- 2016-12-21 LT LTEP16820005.3T patent/LT3393478T/lt unknown
-
2018
- 2018-06-17 IL IL260076A patent/IL260076A/en unknown
- 2018-06-21 ZA ZA2018/04155A patent/ZA201804155B/en unknown
- 2018-06-21 PH PH12018501339A patent/PH12018501339A1/en unknown
-
2020
- 2020-03-17 CY CY20201100245T patent/CY1122835T1/el unknown
-
2022
- 2022-06-21 US US17/845,878 patent/US20230149436A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201803905RA (en) | A hair styling appliance | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201901841TA (en) | Targeting ligands | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201810196RA (en) | Cancer treatments | |
| SG11201803728YA (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201803951QA (en) | Oligonucleotides for inducing paternal ube3a expression | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201810018TA (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs |